Print(PDF/145KB) Sep. 01, 2017 Corporate

Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) today announced that the following organizational realignment and Changes in the posts assumed by Executive Officers and other key positions, effective October 1, 2017:

Ⅰ. Organizational Realignment (effective October 1, 2017)

Drug Research (Division)

  1. Drug Research Division is renamed (in Japanese language only).
  2. Research Planning & Intelligence is renamed to Research Planning & Coordination.
  3. Research Administration is dissolved and its functions are transferred to Research Planning & Coordination and Corporate Service Center.
  4. Innovative Drug Discovery Laboratories and Drug Development Research Laboratories are reorganized into Pharmacology Research Unit and Chemistry Research Unit.
  5. Preclinical Research Laboratories is renamed to Preclinical Research Unit.
  6. Platform Technology Research Unit is created.

Sumitomo Dainippon Pharma will apply a "Project-based Research Management System" by appointing Project Leaders and Project Directors in the Drug Research Division, which is the highlight of this renaming/reorganizing, to strongly accelerate the drug discovery research projects.
Project Leaders are primarily responsible for advancing the drug discovery research projects they are in charge of, while the Project Directors are responsible for strategic proposal regarding conceptual ideas of new research programs and enrichment of research portfolio in Drug Research Division as a whole.
The Drug Research Division will work as one team to effectively maximize the research outcomes, advancing the drug discovery research projects and increasing the research success rate. The Project Leaders will take the initiative in such research team efforts.

Drug Development (Division)

  1. Project Management is renamed to Development Planning & Management.
  2. Development Administration is dissolved.
  3. Development Regulatory Affairs is created.

Ⅱ. Changes in Executive Officers

Changes in the posts assumed by Executive Officers (effective October 1, 2017)

Post as of October 1, 2017 Current post Name
Member, Board of Directors,
Executive Officer
Senior Executive Research Director, Drug Research Division
Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center
Member, Board of Directors,
Executive Officer
Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Drug Research Division
Toru Kimura
Executive Officer
Executive Research Director, Drug Research Division
Executive Officer
Executive Director, Drug Research Division
Hideyuki Harada

Ⅲ. Changes in Personnel (effective October 1, 2017)

Corporate Departments

Position as of October 1, 2017 Current position Name
Senior Strategic Officer - North America non-oncology business Senior Strategic Officer - International business Shinichiro Katayanagi
Deputy Senior Director, Corporate Service Center Senior Director, Research Administration Masashi Yabuki

Drug Research (Division)

Position as of October 1, 2017 Current position Name
Project Director, Early-phase Drug Research Senior Director, External Innovation Development Office Masakazu Hashimoto
Project Director, Late-phase Drug Research Senior Director, Innovative Drug Discovery Laboratories Takeo Ishiyama
Senior Director, Research Planning & Coordination Senior Director, Research Planning & Intelligence Setsuko Yamamoto
Senior Director, External Innovation Development Office Senior Director, Drug Development Research Laboratories Isao Shimizu
Senior Director, Pharmacology Research Unit Director, Innovative Drug Discovery Research Management Group, Innovative Drug Discovery Laboratories Michiko Ono
Senior Director, Chemistry Research Unit Director, Drug Development Chemistry Group I, Drug Development Research Laboratories Katsunori Tsuboi
Senior Director, Preclinical Research Unit Senior Director, Preclinical Research Laboratories Kiyoko Bando
Senior Director, Platform Technology Research Unit
Senior Director, Genomic Science Laboratories
Senior Research Fellow, Molecular Pathophysiology Research Hidetaka Nagata

Drug Development (Division)

Position as of October 1, 2017 Current position Name
Senior Director, Development Planning & Management Senior Director, Project Management Teruya Murata
Senior Director, Development Regulatory Affairs
Director, Development RA Group, Development Regulatory Affairs
Director, Development Regulatory Affairs Group, Clinical Research Kenichi Otani

Sales & Marketing (Division)

Position as of October 1, 2017 Current position Name
Deputy Executive Director, Sales & Marketing Division
Senior Director, Sales & Marketing Management
Senior Director, Sales & Marketing Management Takuya Taguchi
Senior Director, Distribution Management
Director, Wholesaler Service Group, Distribution Management
Senior Director, Distribution Management Toshinobu Shiina
Senior Director, Kita-Kanto Branch Deputy Senior Director, Hospital Promotion, Kyushu Branch Hiroshi Takaoka
Senior Director, Yokohama Branch Deputy Senior Director, Hospital Promotion, Tokai Branch Yasutoshi Araki
Deputy Senior Director, Hospital Promotion, Tokai Branch Director, Osaka Psychiatry Group III, Hospital Promotion, Osaka Branch Hidekatsu Kuroda
Senior Director, Keiji-Hokuriku Branch Deputy Senior Director, Hospital Promotion, Osaka Branch Takayuki Sato
Senior Director, Osaka Branch
Deputy Senior Director, Hospital Promotion, Osaka Branch
Senior Director, Osaka Branch Masaichi Fujimoto
Senior Director, Kyushu Branch
Deputy Senior Director, Hospital Promotion, Kyushu Branch
Senior Director, Yokohama Branch Koji Yamazaki

Inquiries from the Press